Does Quartz Health Solutions Cover Dupixent? What Women Need to Know

The Short Answer on Quartz and Dupixent Coverage

Quartz Health Solutions, a Wisconsin-based not-for-profit insurer serving the Upper Midwest, does include dupilumab (Dupixent) on its specialty drug formulary. Coverage is not automatic. You will need a prior authorization (PA) approved before your pharmacy can dispense the drug, and many plans also impose step therapy, meaning you may need to document failure of at least one conventional treatment first.

The specific requirements depend on which Quartz plan you hold (commercial HMO, PPO, Medicaid, or a marketplace plan) and which FDA-approved indication your clinician is prescribing for. For women, the stakes are particularly high: atopic dermatitis affects approximately 16.7% of adult women in the United States, a rate meaningfully higher than in men, and estrogen fluctuations across the menstrual cycle can trigger or worsen flares.

Why Quartz Requires Prior Authorization

Dupixent carries a list price of approximately $38,000 to $50,000 per year, placing it firmly in the specialty tier where insurers apply the most stringent utilization management. Prior authorization exists to confirm that:

• The diagnosis matches an FDA-approved indication
• Conventional therapies have been tried and have failed or are medically contraindicated
• Prescribing is by or in consultation with a relevant specialist (dermatologist, allergist, pulmonologist)

This is not unique to Quartz. Most commercial insurers and all Medicaid programs apply similar controls to biologic agents.

Which Indications Are Most Likely Covered

The FDA has approved dupilumab for six indications as of 2024, and Quartz coverage criteria tend to mirror FDA labeling:

1. Moderate-to-severe atopic dermatitis (age 6 months and older)
2. Moderate-to-severe asthma with an eosinophilic phenotype or oral corticosteroid dependence (age 6 and older)
3. Chronic rhinosinusitis with nasal polyps (CRSwNP) (adults)
4. Eosinophilic esophagitis (EoE) (age 12 and older, weight at least 40 kg)
5. Prurigo nodularis (adults)
6. COPD with type-2 inflammation and an FEV1 of <70% predicted

For women, atopic dermatitis and asthma account for the largest share of Dupixent prescriptions, and both carry sex-specific physiology that your prescriber should document explicitly in the PA request.

How the Prior Authorization Process Works

Getting a PA approved for Dupixent through Quartz follows a predictable pattern, and knowing each step saves weeks of delay.

Step 1: Your Clinician Submits the PA Request

Your dermatologist, allergist, or other specialist initiates the request. The PA form typically asks for:

• ICD-10 diagnosis code and disease severity documentation (IGA score, EASI score, or spirometry for asthma)
• Prior treatment history: names, doses, durations, and documented failure or intolerance
• Specialist involvement confirmation
• For women of reproductive age: pregnancy status, contraception use (relevant to the safety discussion, not a coverage criterion itself)

A complete, well-documented PA submission reduces the chance of a technical denial. Incomplete submissions are the single most common reason for an initial rejection.

Step 2: Step Therapy Requirements

Quartz, like most payers, requires documented failure of step therapy before approving a biologic. For atopic dermatitis, this typically means:

• Adequate trial (usually 8-12 weeks) of medium-to-high-potency topical corticosteroids
• Trial of a topical calcineurin inhibitor (tacrolimus or pimecrolimus) if steroids are contraindicated or have failed
• For severe disease: documented trial of a systemic immunosuppressant (methotrexate, cyclosporine, azathioprine, or mycophenolate) unless medically contraindicated

Women experience an additional consideration here: cyclosporine and methotrexate are both teratogenic and require reliable contraception, which means that for a woman who is pregnant, planning pregnancy, or unwilling to use contraception, step therapy may be medically inappropriate. Your clinician can document this as a contraindication to bypass step therapy entirely. This is a legitimate and frequently successful approach.

Step 3: Decision Timeline

Federal law (under the ACA and state insurance regulations) requires insurers to issue standard PA decisions within 72 hours and urgent PA decisions within 24 hours. Wisconsin state law adds additional consumer protections. If Quartz has not responded within that window, your prescriber can escalate.

What to Do If Quartz Denies Coverage

A denial is not the end. Roughly 50-60% of specialty biologic denials are overturned on first appeal when the appeal includes complete clinical documentation.

Filing the First-Level Appeal

You have the right to appeal any adverse coverage determination. Your clinician should submit:

• A letter of medical necessity written specifically for your case, citing published clinical guidelines
• Peer-reviewed evidence supporting Dupixent's efficacy for your indication. For atopic dermatitis, the SOLO 1 and SOLO 2 trials showed 36-38% of patients achieving IGA 0 or 1 at week 16 on dupilumab versus 8-10% on placebo. These are strong numbers and should be named explicitly.
• Documentation of why alternative therapies have failed or are contraindicated
• For women: sex-specific documentation of disease severity tied to hormonal fluctuations (cycle-related flares, postpartum exacerbation, perimenopausal worsening)

External Independent Review

If Quartz upholds the denial after internal appeal, you can request an external independent review through the Wisconsin Office of the Commissioner of Insurance. The external reviewer is a clinician with no financial relationship to Quartz. Approval rates at this stage vary but are meaningful.

Expedited Review

If your condition is severe and delay would cause serious harm, request an expedited review. This applies to women with severe, infected eczema; poorly controlled asthma during pregnancy; or other urgent clinical scenarios.

Dupixent Costs, Copay Cards, and Manufacturer Assistance

Even with insurance approval, the specialty-tier cost share can be significant. Here is what is available.

The Dupixent MyWay Program

Sanofi and Regeneron offer the Dupixent MyWay copay assistance program, which may reduce your out-of-pocket cost to $0 per month if you have commercial insurance. This program does not apply to patients with government insurance (Medicare, Medicaid, or CHIP), and eligibility requirements apply. Call 1-844-DUPIXENT or visit the manufacturer's website to enroll.

Patient Assistance for Uninsured or Underinsured Women

If you do not have insurance or are denied coverage, the Dupixent MyWay Patient Assistance Program may provide the medication at no cost based on income criteria. Women on marketplace plans with high deductibles, women in the Medicaid coverage gap in states that have not expanded Medicaid, and uninsured women are the most likely candidates.

Biosimilar Timeline

No FDA-approved biosimilar for dupilumab exists as of early 2025. When biosimilars enter the market, they will likely reduce both list price and insurer resistance. Watch this space.

Why Dupixent Matters Specifically for Women

Women are disproportionately affected by the conditions Dupixent treats, and female-specific physiology shapes both disease severity and treatment response in ways that most insurance coverage articles do not address. This framework is WomanRx's synthesis of the clinical literature as it applies across life stages.

Across the Reproductive Years

Estrogen and progesterone fluctuate across the menstrual cycle, and both cytokines (particularly IL-4 and IL-13, the exact targets of dupilumab) and mast cell activity shift with these hormones. Research published in the Journal of Investigative Dermatology has shown that a subset of women with atopic dermatitis experience premenstrual flares, likely mediated by progesterone-driven upregulation of Th2 inflammation. Dupilumab's mechanism directly addresses this pathway, which may explain why some women see more consistent control with a biologic than with topical-only therapy.

Women with PCOS are at elevated risk for skin barrier dysfunction and seborrheic dermatitis, conditions that overlap with and can worsen atopic dermatitis. If you have PCOS and moderate-to-severe eczema, documenting the connection in your PA request strengthens the medical necessity argument.

Asthma also worsens in a subset of women during the luteal phase of the menstrual cycle, a phenomenon called perimenstrual asthma, affecting an estimated 30-40% of asthmatic women. For women whose asthma is eosinophilic and cycle-linked, dupilumab is a biologically rational treatment choice.

Trying to Conceive and Fertility Considerations

If you are trying to conceive, the conventional immunosuppressants used as step therapy before Dupixent (methotrexate, mycophenolate, cyclosporine) each carry significant reproductive risks:

• Methotrexate is a known teratogen and abortifacient; it requires contraception during use and for at least one ovulatory cycle after stopping
• Mycophenolate carries a black box warning for pregnancy loss and fetal malformations and requires two forms of contraception
• Cyclosporine has less definitive teratogenicity data but is generally avoided in planned pregnancy

For women who are actively trying to conceive, these step therapy requirements are often medically inappropriate, and your prescriber should document this clearly in the PA to bypass step therapy.

Pregnancy

Dupixent is not formally contraindicated in pregnancy, but human safety data are limited. The ongoing ARIA registry (Atopic Dermatitis Dupixent Registry) is collecting prospective data on dupilumab exposure in pregnancy, but enrollment is still active and results are not yet comprehensive.

What is known: dupilumab is a large-molecule IgG4 antibody. IgG antibodies cross the placenta actively during the second and third trimesters via the neonatal Fc receptor. This means fetal exposure increases as pregnancy progresses. The FDA label states that available human data are insufficient to establish a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal studies using doses up to 10 times the human dose showed no harm to the fetus.

In practice, most dermatologists and allergists will continue dupilumab in pregnant women with moderate-to-severe disease that is inadequately controlled by topical therapy alone, because uncontrolled atopic disease during pregnancy also carries risks (secondary infection, sleep deprivation, psychological distress, and systemic inflammation). This is a shared decision-making conversation, not a categorical stop.

If you discover you are pregnant while on Dupixent, do not stop abruptly without speaking to your prescriber. Call within 24-48 hours to discuss a plan.

Lactation

Dupilumab is a large protein molecule. Large-molecule biologics typically transfer into breast milk in very small amounts and are largely destroyed by infant gastrointestinal proteases before systemic absorption can occur. No published human data specifically quantify dupilumab transfer into breast milk, which the FDA label acknowledges. Given the low expected oral bioavailability of a protein drug in an infant, most experts consider the risk of clinically significant infant exposure to be low, but the absence of direct data means you should discuss this with your prescriber and a lactation medicine specialist rather than making the decision alone.

For women with postpartum atopic dermatitis flares (which are common given the immune shifts of the postpartum period), dupilumab may be considered on a case-by-case basis.

Perimenopause and Menopause

Estrogen decline in perimenopause and menopause affects skin barrier integrity, increases skin dryness and itch, and can unmask or worsen previously mild atopic dermatitis. A 2022 analysis in Menopause found that postmenopausal women have measurably reduced transepidermal water loss capacity and skin hydration compared with premenopausal controls.

For perimenopausal and postmenopausal women newly presenting with moderate-to-severe eczema, dupilumab is just as appropriate an option as it is for younger women, and the step therapy requirements apply equally. If you are on menopausal hormone therapy (MHT), there is no known pharmacokinetic interaction with dupilumab.

Who This Treatment Is and Is Not Right For

Understanding fit helps you frame the conversation with your prescriber and strengthens your PA documentation.

Women Who Are Strong Candidates

• Women with moderate-to-severe atopic dermatitis (IGA 3-4 or EASI >16) who have failed or cannot tolerate topical steroids and at least one systemic agent
• Women with uncontrolled eosinophilic asthma, especially those with perimenstrual exacerbation or corticosteroid dependence
• Women with CRSwNP requiring repeated sinus surgery or oral steroid bursts
• Women with PCOS in whom systemic immunosuppressants are poorly tolerated or carry reproductive risk
• Perimenopausal or postmenopausal women with newly worsened atopic dermatitis where declining estrogen has compromised skin barrier function

Women Who Should Pause Before Starting

• Women actively planning pregnancy should discuss timing with their prescriber, not because dupilumab is clearly harmful but because evidence is still accumulating
• Women with a history of parasitic (helminth) infection should be evaluated before starting, as dupilumab suppresses the Th2 response that helps control certain parasites
• Women with conjunctivitis or eye-surface problems should note that conjunctivitis is the most common dupilumab side effect, occurring in up to 10% of patients with atopic dermatitis in the SOLO trials, and should have ophthalmology access

Practical Steps to Maximize Your Chances of Coverage

1. Choose a specialist prescriber. Quartz is more likely to approve a PA from a board-certified dermatologist or allergist than from a primary care provider alone, even if the PCP is managing your care.
2. Get your severity scores documented in writing before the PA is submitted. EASI, IGA, DLQI (Dermatology Life Quality Index), or ACQ (Asthma Control Questionnaire) scores give the PA reviewer objective data.
3. Compile your treatment history in a timeline format. Dates, drug names, doses, durations, and why each was stopped.
4. If step therapy fails on medical necessity grounds (pregnancy, fertility plans, teratogen contraindication), ask your prescriber to state this explicitly using those exact words.
5. Enroll in Dupixent MyWay before your first fill, even if you expect insurance to cover most of the cost. Enrollment is free and can act as a bridge if coverage lapses.
6. If denied, appeal within the timeframe stated on the denial letter (typically 180 days for commercial plans).
7. Keep records. Every phone call to Quartz should be documented with the date, time, representative name, and what was said.

A Note on Evidence Gaps in Women

Women have been historically under-represented in biologic clinical trials. The SOLO 1, SOLO 2, and LIBERTY AD CHRONOS trials that formed the basis of dupilumab's atopic dermatitis approval enrolled roughly 50-55% female participants, which is better than many trials but still does not provide subgroup analyses powered to detect sex-specific differences in efficacy or adverse events. Data on dupilumab across the menstrual cycle, during pregnancy, and in the postmenopausal skin context remain limited. This is an honest gap, not a reason to avoid the drug, but it means your experience may differ from the average trial participant in ways that are not yet fully characterized.